---
document_datetime: 2023-09-21 19:16:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neupopeg-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: neupopeg-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7417178
conversion_datetime: 2025-12-18 09:58:05.804341
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Neupopeg

## Procedural steps taken and scientific information after the authorisation Changes made after 01/02/2004

For procedures finalised before 01/02/2004, please refer to module 8A

## MAJOR CHANGES 1

| No      | Scope                                                                                                                                                                                                                        | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0037 | Update of Summary of Product Characteristics The MAHhas applied to amend section 4.8 of the SPC to included information about the potential for elevated Liver Function Tests (LFTs) in patients treated with pegfilgrastim. | 19/03/2008          | 18/04/2008                               | SPC                              | longer The MAHhas applied to amend section 4.8 of the SPC to included information about the potential for elevated Liver Function Tests (LFTs) in patients treated with pegfilgrastim.                                                                                                         |
| II/0036 | Change(s) to the manufacturing process for the active substance                                                                                                                                                              | 21/02/2008          | 26/02/2008                               | no                               |                                                                                                                                                                                                                                                                                                |
| II/0035 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                             | product 13/12/2007  | 17/01/2008                               | SPC, PL                          | Amendment to section 4.8 of the SPC with regard to the frequency of Sweet's syndrome. The Package Leaflet has also been amended accordingly.                                                                                                                                                   |
| II/0034 | Change(s) to the manufacturing process for the active substance                                                                                                                                                              | 15/11/2007          | 21/11/2007                               |                                  |                                                                                                                                                                                                                                                                                                |
| II/0033 | Medicinal Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                   | 18/10/2007          | 20/11/2007                               | SPC, PL                          | Update of section 4.8 of the Summary of Product Characteristics to include: injection-site reactions, erythema and flushing. The package leaflet is updated accordingly. This variation fulfils a commitment made by the MAHwhich resulted from the recent renewal procedure.                  |
| II/0032 | Update of Summary of Product Characteristics                                                                                                                                                                                 | 18/10/2007          | 20/11/2007                               | SPC                              | Update of Summary of Product Characteristics to amend sections 4.2 and 5.2 with data from a study investigating the effects of renal impairment on the pharmacokinetics of pegfilgrastim. This variation fulfils a commitment made by the MAHwhich resulted from the recent renewal procedure. |
| R/0031  | Renewal of the marketing authorisation                                                                                                                                                                                       | 24/05/2007          | 16/07/2007                               |                                  |                                                                                                                                                                                                                                                                                                |

1 Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments

2 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                        | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030 | Change(s) to the manufacturing process for the finished product                                                              | 22/03/2007          | 27/03/2007                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0029 | Change to the test procedure and/or specification of a raw material                                                          | 22/03/2007          | 27/03/2007                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0028 | Change(s) to the manufacturing process for the active substance                                                              | 24/01/2007          | 29/01/2007                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0027 | Update of Summary of Product Characteristics and Package Leaflet                                                             | 16/11/2006          | 03/01/2007                               | SPC, Annex II, Labelling, PL     | longer authorised Update to sections 4.4 and 4.8 of the SPC following a review of the Company Core Data Sheet and a recent assessment of the 7th PSUR. Update to sections 2 and 4 of the Package Leaflet with regards to information on allergy to latex and very rare events of cutaneous vasculitis. Update to section 6 of the Package Leaflet on how to administer the medicinal product. |
| II/0026 | Change(s) to the manufacturing process for the active substance                                                              | 27/07/2006          | 18/08/2006                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0024 | Change(s) to the manufacturing process for the active substance                                                              | 27/04/2006          | 03/05/2006                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0021 | New presentation(s) The Marketing Authorisation Holder applied to add a new prefilled pen presentation to the product range. | 15/09/2005          | product 28/10/2005                       | no SPC, Labelling, PL            |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0020 | Update of Summary of Product Characteristics and Package Leaflet                                                             | 23/06/2005          | 01/08/2005                               | SPC, PL                          | Sections 4.4 and 4.8 of the SPC were amended to update the safety information in relation to pulmonary effects and to add \"leucocytosis\" further to the assessment of the 5th PSUR. The Patient Leaflet was amended accordingly.                                                                                                                                                              |
| II/0019 | Change(s) to the manufacturing process for the active substance                                                              | 27/07/2005          | 31/08/2005                               | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0018 | Medicinal Update of Summary of Product Characteristics                                                                       | 16/03/2005          | 27/04/2005                               | SPC                              | Sections 4.8 and 5.1 of the SPC were amended to reflect the results from a phase 3 study showing that the addition of pegfilgrastim to docetaxel in patients with breast cancer had a beneficial effect on the primary endpoint of the incidence of febrile neutropenia.                                                                                                                      |
| II/0017 | Quality changes The Marketing Authorisation Holder applied to update the manufacturing process for the active substance.     | 16/03/2005          | 21/03/2005                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0016 | Update of Summary of Product                                                                                                 | 15/09/2005          | 28/10/2005                               | SPC                              | Sections 4.8 and 5.1 of the SPC were updated to reflect new data on the                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                 | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|-------------------------------------------------------------------|
|         | Characteristics                                                                                                       |                     |                                          |                                  | use of Neupopeg in patients with de novo acute myeloid leukaemia. |
| II/0015 | Quality changes The Marketing Authorisation Holder applied to change the active substance and product specifications. | 16/03/2005          | 21/03/2005                               |                                  | authorised                                                        |
| II/0014 | Update of Summary of Product Characteristics and Package Leaflet                                                      | 15/12/2004          | 25/01/2005                               | SPC, PL                          |                                                                   |
| II/0010 | Change(s) to the manufacturing process for the active substance                                                       | 23/06/2004          | 29/06/2004                               |                                  |                                                                   |
| II/0008 | Change(s) to the manufacturing process for the active substance                                                       | 29/07/2004          | 02/08/2004                               |                                  |                                                                   |
| II/0005 | Change(s) to the manufacturing process for the active substance                                                       | 22/04/2004          | 27/04/2004                               | longer                           |                                                                   |

## MINOR CHANGES 3

| No      | Scope                                                                                                                                                                         | Product Information affected 2   | Date 4     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------|
| IA/0025 | 38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                   |                                  | 17/01/2006 |
| IB/0023 | 37_a_Change in the specification of the finished product - tightening of specification limits                                                                                 |                                  | 10/01/2006 |
| IA/0022 | 28_Change in any part of primary packaging material not in contact with finished product                                                                                      |                                  | 29/06/2005 |
| IB/0013 | 12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter                                                                                    |                                  | 09/08/2004 |
| IA/0012 | 28_Change in any part of primary packaging material not in contact with finished product 41_a_01_Change in pack size - change in no. of units within range of appr. pack size | SPC, Labelling, PL               | 18/06/2004 |
| IB/0011 | 42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                       | SPC                              | 01/07/2004 |

Medicinal product no longer authorised

3 Minor changes e.g. Type I variations and Notifications

4 Date of entry into force of the change